Healthcare
Live Price
Offline$0.0001
-75.00% today
1Y Change
-99.63%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Syros Pharmaceuticals, Inc. (SYRS) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -33.2%, EPS growth of +22.4%, a dividend yield of 0.0%. What stands out right now is revenue -33.2%, EPS +22.4%, free cash flow +11.5% with operating margin -1298.2% and ROIC -91.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYRS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYRS Max Drawdown
-99.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYRS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.0M
-86.9% YoY
FY Net Income
-$75.4M
+10.2% YoY
Free Cash Flow
-$72.9M
-20.1% YoY
Revenue Growth
-33.2%
EPS Growth
+22.4%
Gross Margin
77.3%
Net Margin
-1656.3%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 10M | 15M | 23M | 15M | 2M |
| Gross Profit | 8M | 12M | 23M | 15M | 2M |
| Operating Income | -129M | -136M | -99M | -82M | -78M |
| EBITDA | -157M | -88M | -80M | -79M | -73M |
| Net Income | -165M | -95M | -87M | -84M | -75M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 140M | 167M | 92M | 174M | 41M |
| Total Assets | 168M | 244M | 183M | 213M | 150M |
| Total Liabilities | 152M | 117M | 98M | 123M | 71M |
| Shareholder Equity | 17M | 128M | 85M | 91M | 79M |
| Total Debt | 62M | 64M | 65M | 66M | 26M |
| Net Debt | -77M | -104M | -27M | -108M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
60M
-5.0% YoY
Capital Expenditures
13M
-278.8% YoY
Free Cash Flow
73M
-20.1% YoY
Key ratios
Gross Margin
77.3%
Operating Margin
-1298.2%
Net Margin
-1656.3%
ROE
-227.9%
Debt / Equity
3.73x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.